Example: Heart Attack

Search clinical trials for: 4'-N-benzoylstaurosporine

Total 49 results

NCT04496999

Not yet recruiting

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Conditions: AML, Adult
NCT04477291

Not yet recruiting

A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT04385290

Not yet recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

Conditions: Acute Myeloid Leukemia
NCT04174612

Recruiting

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
NCT04097470

Recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Conditions: AML/MDS
NCT04075747

Recruiting

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT04027309

Recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
NCT03951961

Recruiting

Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia, Adult
NCT03900949

Recruiting

Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03836209

Recruiting

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03760445

Withdrawn

HDM201 Added to CT in R/R or Newly Diagnosed AML

Conditions: Leukemia, Myeloid, Acute
NCT03686345

Recruiting

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

Conditions: Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
NCT03680677

Suspended

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Conditions: Leukemia, Acute; MDS
NCT03609060

Active, not recruiting

Dexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia
NCT03591510

Suspended

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Conditions: FLT3-mutated Acute Myeloid Leukemia
NCT03512197

Active, not recruiting

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia (AML)
NCT03379727

Active, not recruiting

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.

Conditions: Acute Myeloid Leukemia
NCT03280030

Active, not recruiting

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Conditions: Acute Myeloid Leukemia
NCT03258931

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Conditions: Newly Diagnosed FLT3 Mutated AML
NCT03226418

Recruiting

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

Conditions: Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
NCT03207334

Withdrawn

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Conditions: Acute Myeloid Leukemia
NCT03114228

No longer available

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Conditions: FLT3-mutated Acute Myeloid Leukemia
NCT03092674

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
NCT02756962

Recruiting

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Conditions: Acute Myeloid Leukemia
NCT02723435

Withdrawn

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Conditions: Acute Myeloid Leukemia With Gene Mutations; Adult Acute Myeloid Leukemia in Remission
NCT02665065

Recruiting

Study of Iomab-B Prior to Hematopoietic Cell Transplant vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute; Leukemia, Myeloid, Acute; Acute Myelogenous Leukemia; Leukemia, Acute Myelogenous; Myelogenous Leukemia, Acute; AML; Bone Marrow Transplant
NCT02634827

Terminated

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation; Acute Myeloid Leukemia With Gene Mutations; FLT3 Tyrosine Kinase Domain Point Mutation; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
NCT02624570

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Conditions: Acute Myeloid Leukemia (AML) With; FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
NCT02115295

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Conditions: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10 Percent or More of Peripheral Blood White Cells; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
NCT02078609

Completed

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Conditions: AML and High Risk MDS
NCT01920204

Unknown status

Midostaurin in Indolent Systemic Mastocytosis

Conditions: Indolent Systemic Mastocytosis
NCT01883362

Completed

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Conditions: Acute Myeloid Leukemia
NCT01846624

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults; AML (Adult) With 11q23 (MLL) Abnormalities; AML (Adult) With Del (5q); AML (Adult) With Inv (16) (p13; q22); AML (Adult) With t (16;16) (p13; q22); AML (Adult) With t (8; 21) (q22; q22); Secondary AML (Adult); Untreated AML (Adult)
NCT01830361

Completed

Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML

Conditions: Acute Myeloid Leukemia
NCT01477606

Completed

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Conditions: Acute Myeloid Leukemia
NCT01429337

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Conditions: Hepatic Impairment
NCT01282502

Completed

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

Conditions: Adenocarcinoma of the Rectum
NCT01202877

Completed

PKC412 and 5-Azacytidine

Conditions: Leukemia
NCT01174888

Completed

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
NCT01161550

Completed

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Conditions: Leukemia, Myeloid, Acute
NCT01130662

Completed

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT01093573

Completed

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Conditions: Untreated Adult Acute Myeloid Leukemia
NCT00866281

Terminated

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
NCT00819546

Active, not recruiting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
NCT00782067

Completed

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Conditions: Leukemia
NCT00651261

Active, not recruiting

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Leukemia
NCT00233454

Completed

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Conditions: Systemic Mastocytosis, Aggressive (ASM); Leukemia, Mast Cell; Hematological Non-mast Cell Lineage Disease (AHNMD)
NCT00093600

Completed

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia (AML)
NCT00045942

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

COOKIE SETTINGS

Search clinical trials for: 4'-N-benzoylstaurosporine